Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sudeep Burman

Trauma Surgery Austin, TX Doctor of Osteopathy

NPI 1114277639 CMS profile 5586

4319 James Casey St Ste 100, Austin, TX 78745

Open in the dashboard

General payments

$71,685

312 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sudeep Burman of Austin, TX is reported in the CMS Open Payments database as having received $71,685 across 312 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Trauma Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,090 50
2024 General $21,027 72
2023 General $13,898 63
2022 General $3,032 29
2021 General $5,262 24
2020 General $13,548 20
2019 General $7,827 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sudeep Burman
  • Trauma Surgery median
  • Middle half of Trauma Surgery
  • National median

In program year 2025, general payments to Sudeep Burman were reported at $7,090. Among 762 Trauma Surgery profiles paid that year, the median was $280 and the middle half received between $87 and $1,585.

Show as a table
Year Sudeep Burman Trauma Surgery median Middle half National median
2019 $7,827 $153 $56–$644 $163
2020 $13,548 $123 $39–$342 $114
2021 $5,262 $142 $45–$556 $132
2022 $3,032 $172 $59–$732 $149
2023 $13,898 $213 $83–$1,200 $160
2024 $21,027 $237 $86–$1,280 $164
2025 $7,090 $280 $87–$1,585 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $37,631 80 payments
  2. CONMED Corporation $7,788 14 payments
  3. Davol Inc. $6,592 63 payments
  4. TELA Bio, Inc. $6,042 34 payments
  5. W. L. Gore & Associates, Inc. $5,449 50 payments
  6. Stryker Corporation $2,091 10 payments
  7. Acera Surgical, Inc. $1,896 17 payments
  8. Distalmotion US $1,388 3 payments
  9. Becton, Dickinson and Company $1,040 9 payments
  10. Medtronic, Inc. $305 4 payments
  11. Other $1,464 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $32,539 13 payments
  2. Travel and Lodging $17,442 62 payments
  3. Food and Beverage $15,049 231 payments
  4. Consulting Fee $6,000 3 payments
  5. Honoraria $520 1 payment
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $125 1 payment
  7. Gift $11 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System Surgery $33,131 78 payments
  2. AIRSEAL $7,788 14 payments
  3. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $4,475 21 payments
  4. Phasix Mesh $3,964 47 payments
  5. GORE BIO-A Tissue Reinforcement $3,047 16 payments
  6. Da Vinci Surgical System Surgery $3,000 1 payment
  7. Restrata Wound Matrix $1,896 17 payments
  8. OviTex 2S $1,534 11 payments
  9. DAVINCI XI $1,500 1 payment
  10. SYNECOR Biomaterial $1,449 18 payments
  11. Other $7,901 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Median for General Surgery: 59

Drug cost

$50

Median for General Surgery: $393

Branded share of claims

0%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tramadol Hcl Generic 15 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$45,573

Medicare's payments for the services billed

Medicare patients

68

Average age 74

Services billed

210

35 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 32%
Ischemic heart disease 32%
Depression 32%
Atrial fibrillation 31%
Cancer 31%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record